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High-dose chemotherapy and autologous hematopoetic cell 
transplantation can rescue no more than 50% of patients with 
relapsed/refractory (RR) Hodgkin lymphoma (HL).
1,2
 The novel 
anti-CD30 brentuximab vedotin (BV), the anti-PD1 nivolumab or 
pembrolizumab, and allogeneic (allo)-HCT represent treatment 
options in this subset. Importantly, the 2015 European and 
American guidelines recommend reduced-intensity conditioning 
allo-HCT for eligible patients relapsed after an autologous 
hematopoetic cell transplantation.
3,4
 
We present a long-term follow-up analysis on 69 consecutive RR 
HL patients treated with allo-HCT, between May 2000 and 
December 2015, at three Transplant Centers in Northwest Italy 
(AOU Città della Salute e della Scienza of Torino, AO Santa Croce e 
Carle of Cuneo, and AO Santi Antonio, Biagio e Cesare Arrigo of 
Alessandria). 
Patient, disease and transplant characteristics are summarized 
in Table 1. Patients received a median of 4 therapy lines (range, 
2–6) before allo-HCT. Forty patients (58%) received an autologous 
hematopoietic cell transplant 7.6 months (range, 1.6–48.2) before 
allo-HCT; 24 patients (35%) underwent a programmed tandem 
auto/allo-HCT. Primary graft failure
5
 occurred in 1 patient (1.5%) 
receiving PBSC from an unrelated donor. 
Median overall survival (OS) from diagnosis was 10.9 years 
(range, 1.18–18.6+). After a median follow-up in survivors of 7.2 
years (range, 0.1–13.8+) from allo-HCT, 5-year OS and relapse-free 
survival (RFS) were 51.4% and 38.9%, respectively (Figures 1a 
and b). Five-year RFS was 45.9% and 12.5% in responsive (CR+PR) 
and non-responsive (others)  patient  cohorts,  respectively,  
(P = 0.008) (Figure 1e). RFS of patients in CR at the time of 
allo-HCT (n = 29) compared with patients in PR (n = 23) did not 
significantly differ (hazard ratio = 1.71, 95% confidence interval (CI) 
0.78–3.72, P = 0.18). There was a trend for better 5-year OS in 
responsive patients as compared with non-responsive, 54.6% vs 
37.5% (P = 0.19). We observed also a trend to better OS in patients 
who developed chronic GvHD compared with patients who did 
not (hazard ratio = 0.65, 95% CI 0.29–1.48, P = 0.3 (57 evaluable 
patients)). 
Overall, 32 patients died mainly because of disease recurrence 
(n = 20). The higher risk of failure in terms of RFS of non-responsive 
patients was confirmed by univariate Cox regression (hazard 
ratio = 2.34, 95% CI 1.22–4.50, P = 0.011). Cumulative incidence of 
non-relapse mortality (NRM) was 17.7% at 5 years (Figure 1c). 
Causes of NRM were hemorrhagic alveolitis (n = 2), infections 
(N = 5) and GvHD (N = 5). Patients younger than 35 years old had a 
Table 1. Patient and disease characteristics 
 
Characteristics Overall 
Patients, n 
Male/female, n (%) 
Median age at allo-HCT, years (range) 
69 
33 (48)/36 (52) 
34 (18–64) 
Disease status at allo-HCT 
CR, n (%) 
PR, n (%) 
Other, n (%) 
Not evaluable, n (%) 
29 (42) 
23 (33) 
16 (23) 
1 (1) 
Stage 
Therapy lines 
⩽ 3, n (%) 
43, n (%) 
Previous auto-HCT 
32 (46) 
37 (54) 
64 (93) 
Immunosuppression  
CNI/MTX  
CNI/MMF 
CNI/CY/MMF 
CNI/alemtuzumab 
53 (77) 
12 (17) 
2 (3) 
2 (3) 
ATG 
Yes, n (%) 
No, n (%) 
35 (51) 
34 (49) 
Conditioning intensity 
RIC or non-myeloabative 
MAC 
64 (93) 
5 (7) 
Donors 
Source of stem cells 
Peripheral blood, n (%) 
Marrow, n (%) 
Cord, n (%) 
61 (88) 
7 (10) 
1 (1) 
Brentuximab vedotin 
Pre-allo-HCT, n (%) 
Post-allo-HCT, n (%) 
No, n (%) 
Not evaluable, n (%) 
Abbreviations: ATG = anti-thymocyte globulin; 
12 (17) 
6 (9) 
49 (71) 
1 (1) 
CNI = calcineurin 
inhibitors; CY = cyclophosphamide; HCT = hematopoietic cell transplant; 
MAC = myeloablative conditioning;  MMF = mycophenolate mofetil; 
MTX = methotrexate; RIC = reduced-intensity conditioning. aOne patient 
was one Ag HLA-mismatched. 
I–II, n (%) 32 (46) 
III–IV, n (%) 36 (52) 
Not evaluable, n (%) 1 (1) 
 
HLA-matched family members, n (%)
a
 28 (41) 
HLA-haploidentical, n (%) 2 (3) 
HLA-matched unrelated, n (%) 38 (55) 
Cord, n (%) 1 (1) 
 
lower NRM than older patients (8.7% vs 27.1%, P = 0.051). NRM 
did not differ between responsive and non-responsive patients 
(SDHR 1.08, 95% CI 0.30–3.96, P = 0.9). 
Cumulative incidence of grade II–IV acute GvHD was 36.7% 
(60 evaluable patients). At follow-up, cumulative incidence of all 
grades of chronic GvHD was 45.6% (57 evaluable patients) 
(Figure 1d). Of note, six additional patients developed chronic 
GvHD after disease relapse likely due to rapid immunosuppression 
taper or subsequent donor lymphocyte infusion (DLI). 
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Figure 1. Kaplan–Meier curves of overall survival (a) and relapse-free survival (b); cumulative incidence curves of relapse, non-relapse mortality 
(c) and cGvHD (d). Kaplan–Meier curves of relapse-free survival (e), and cumulative incidence curves of relapse (f) for patients at least in PR at 
allo-HCT (responsive) and for patients with active disease (unresponsive). cGvHD, chronic GvHD; RI, relapse incidence. 
 
 
Overall, 1-, 3- and 5-year relapse incidence was 31.8%, 41.4% 
and 43.4%, respectively (Figure 1c). Median time to relapse 
was 7.8 months (range, 1.8–45.5). Twenty-one/28 (75%) relapses 
occurred within 1 year from allo-HCT. Patients with non- 
responsive disease had a significantly higher relapse incidence 
than responsive patients, 68.7% vs 35.3% (P = 0.012) (Figure 1f). 
The negative impact of active disease at allo-HCT was confirmed 
by univariate competing-risk regression (SDHR 2.65, 95% CI 
1.26–5.51, P = 0.001). 
Among 28 relapsed patients, 13 (46%) received DLI alone (n = 3), 
with brentuximab (n = 3)  or  with  chemotherapy  (n = 7)  after 
a median of 18.7 months (range, 3.4–50) from allo-HCT. 
The remaining 15 patients received chemotherapy alone or best 
supportive care. DLI were from unrelated (n = 4), matched-related 
siblings (n = 8) and HLA-haploidentical (n = 1) donors. Median 
number of DLI received per patient was 2 (range, 1–7) and the 
median number of CD3
+
 lymphocytes infused was 1 × 10
7
 CD3
+
 
cells/kg (range, 1 × 10
6
–1× 10
8
). Four patients achieved CR, five PR 
and four were unresponsive. The median time to next treatment 
was 11 months (range, 3–123). Post-DLI GvHD occurred in four 
patients, and two of them required immunosuppression. Patients 
who received DLI had a median OS from the time of first relapse of 
4.5 years (range, 1.2–12.2+). At last follow-up, 8 out of 28 relapsed 
patients (29%) were alive. Of those, six had received DLI. 
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Since 2011, BV was used at the conventional dose (1.8 mg/kg IV 
once every 3 weeks) in 18 patients. Twelve patients (67%) received 
BV as bridge to allo-HCT for a median of six cycles (range, 3–13). 
The median time between the last BV cycle and allo-HCT was 
1.7 months (range, 0.3–4). Only three patients failed to achieve at 
least PR, with an overall response rate of 75%. BV was also 
administered as salvage for post-allo-HCT relapse in 6 patients 
(median 11 cycles, range, 7–16), 3 of whom did not respond to 
prior DLI. Two additional patients received DLI after BV. The first 
BV cycle was administered after a median of 6 months from 
allo-HCT (range, 2.6–16.7). Five patients achieved CR and 1 patient 
PR, with a median survival from the first BV cycle of 27.2 months 
(range, 10.5–55.5+). Four of 6 patients were alive at last contact. 
None of the patients treated with BV had unexpected toxicity or 
GvHD flare. One patient developed grade I hematological and 
neurological toxicity, which did not require drug discontinuation, 
and another experienced grade II gastrointestinal toxicity. 
Our report combines a 15-year experience of allo-HCT for RR HL 
in three Italian Transplant Centers after a remarkable median 
follow-up longer than 7 years. Given the long study period, 
transplant preparative regimens and GvHD prophylaxis changed 
over time. Overall, all but five of our patients received reduced- 
intensity conditioning regimens, given that myeloablative con- 
ditionings were commonly associated with worse outcomes in HL 
patients.
6–8
 However, a recent study on 312 patients comparing 
reduced-intensity conditioning and myeloablative allo-HCT hinted 
at a better disease control with the latter due to recent decrease 
in NRM.
9
 
Other recent studies evaluated the impact  of  donor  type 
on clinical outcomes for HD patients.
10,11
 Overall, whether a 
haploidentical donor should be preferred to an unrelated donor, 
especially when HLA mismatches are present, remains a matter of 
debate. In our study, clinical outcomes between related and 
unrelated donor HCT did not differ. 
Overall, the main cause of treatment failure was relapse. Of 
note, most relapses (75%) occurred within 1 year from allo-HCT. 
In several studies, chronic GvHD appeared to confer protection 
against disease recurrence.
12,13
 We observed only a trend toward 
a decreased relapse incidence in patients with chronic GvHD. The 
therapeutic potential of a graft-versus-lymphoma effect in our 
series is suggested by the long-term survival of patients after DLI. 
The efficacy of DLI in HL was previously described by Peggs et al.
14
 
in patients who underwent in vivo T-cell depleted allo-HCT. 
Nineteen of 24 relapsed patients (79%) responded to DLI (14 CRs, 
5 PRs), with a 4-year OS from relapse of 59%. 
Given the poor prognostic features of patients included in this 
study, the 5-year OS higher than 50% is highly encouraging, 
and similar to those reported by the EBMT consortium
15
 on 92 HL 
patients with 4 years of follow-up and 4-year OS of 41%. 
Importantly, our long follow-up allowed to observe that both OS 
and RFS curves reached a plateau after around 5 years, which 
confirmed the curative potential of allo-HCT in RR HL. Several 
studies showed the dismal outcome of patients with active 
disease at the time of allo-HCT.
7,12–14
 In our report, the presence of 
responsive disease was the only statistically significant predictor of 
lower relapse incidence and better RFS. However, we only 
observed a trend toward better OS between responsive and 
non-responsive patients. This may be due to long-term 
responses in relapsed patients where a prolonged and persistent 
graft-versus-lymphoma effect may have played a pivotal role. 
Evidence of very high response rates obtained with novel 
agents are emerging in RR HL. However, response duration after 
BV in early phase trials was in the order of 10 months only and 
follow-up after anti-PD1s is too short to draw conclusions.
16–19
 
Several other groups reported promising results with BV prior to 
allo-HCT, or as salvage for post-allo-HCT relapse.
20–22
 In our 
experience, the use of BV did not add unexpected toxicity and 
showed efficacy on disease reduction before allo-HCT. This is of 
 
 
particular interest, given that disease status at allo-HCT was the 
only predictor of RFS. Furthermore, BV played a role, alone or in 
association with DLI, for the treatment of post-transplant disease 
recurrence.
23
 
In conclusion, our study showed that allo-HCT is feasible and 
effective in RR HL. The plateau of survival curves was more than 
likely due to a prolonged and persistent graft-versus-lymphoma 
effect. BV was safe and effective as a bridge to allo-HCT in the 
majority of treated patients and as rescue in post-allo-HCT relapse. 
A combination strategy of allo-HCT with BV and/or other novel 
agents may further improve clinical outcomes of cell therapies in 
HL and should be evaluated in prospective trials. 
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